Quintessence Biosciences, Inc. Presents Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Meeting
6/8/2010 11:22:55 AM
More...
|
Quintessence Biosciences, Inc. Presents Efficacy Data for Conjugates of Clinical Candidate QBI-139 at Cancer Meeting
4/21/2009 1:33:51 PM
More...
|
Patients Now Enrolling in Phase I Human Trial for Quintessence Biosciences, Inc. Cancer Drug, QBI-139
3/26/2009 10:46:57 AM
More...
|
Quintessence Biosciences, Inc. Cancer Drug, QBI-139, Clears FDA Review to Start Phase I Human Trial
12/5/2008 2:30:43 PM
More...
|
Quintessence Biosciences, Inc. Presents Efficacy Data for Next Generation Evade™ Ribonucleases at Cancer Meeting
10/23/2008 3:26:35 PM
More...
|
Federal Contract Awarded to Quintessence Biosciences, Inc. Funding will Support Development of Next Generation EVade(TM) Ribonuclease Drug Candidates
10/9/2008 1:45:02 PM
More...
|
Quintessence Biosciences, Inc. Presents Pre-clinical Toxicology Data at Cancer Meeting
4/14/2008 2:11:01 PM
More...
|
Althea Technologies, Inc. Chosen by Quintessence Biosciences, Inc. to Produce Lead Protein Oncology Drug
2/5/2008 10:16:56 AM
More...
|
Two Federal Grants Support Quintessence Biosciences, Inc.
11/30/2007 7:54:56 AM
More...
|
Madison Biotechs Get Commerce Grants
10/19/2005 5:13:14 PM
More...
|
|